Kombi-Kalz

Colecalciferol, the active ingredient in Kombi-Kalz, is a Vitamin D3 and calcium supplement presented as an oral dosage form for oral use. It helps address calcium and vitamin D deficiencies and supports bone health in individuals at risk of osteopenia or osteoporosis.

GNH USA supplies Kombi-Kalz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality and regulatory compliance across markets. The company adheres to EU GMP standards and provides reliable logistics for global distribution.

Kombi-Kalz is a nutritional supplement that acts on calcium and vitamin D pathways to correct deficiencies and support skeletal health.

- Calcium deficiency: restores normal calcium levels and promotes bone mineralization. - Vitamin D deficiency: supplies colecalciferol to improve serum 25‑OH vitamin D concentrations. - Bone health maintenance: assists in maintaining bone density and reducing risk of osteoporotic fractures. - Osteopenia risk management: provides essential nutrients to support bone remodeling in at‑risk adults. - Post‑menopausal bone support: helps counteract accelerated bone loss associated with menopause.

Kombi-Kalz may cause adverse reactions, most of which are mild and reversible.

Common Side Effects: - Nausea: occasional mild stomach upset. - Constipation: transient changes in bowel movements. - Flatulence: increased intestinal gas. - Headache: mild, self‑limiting. - Metallic taste: brief alteration in taste perception.

Serious or Rare Side Effects: - Hypercalcemia: elevated blood calcium levels, potentially causing weakness or cardiac arrhythmia. - Kidney stones: calcium precipitation in the urinary tract. - Allergic reaction: rash, itching, or swelling of the face, lips, or tongue. - Hypervitaminosis D: excessive vitamin D leading to toxicity symptoms. - Severe gastrointestinal bleeding: rare but serious abdominal pain with blood loss.

Before initiating Kombi-Kalz, consider the following safety measures.

- Baseline assessment: evaluate serum calcium and 25‑OH vitamin D levels. - Renal function: monitor kidney function in patients with chronic kidney disease. - Hypercalcemia risk: avoid use in individuals with known hypercalcemia or hyperparathyroidism. - Sarcoidosis caution: vitamin D may exacerbate calcium accumulation in granulomatous diseases. - Pregnancy and lactation: use only if the prescriber determines potential benefit outweighs risk. - Store at ambient temperature: keep below 25 °C, retain in original packaging, and protect from moisture.

Kombi-Kalz can interact with other medicines; awareness of the interaction level helps manage risk.

Major Interactions (Avoid): - Thiazide diuretics: may increase risk of hypercalcemia. - Vitamin A excess: combined high doses can precipitate hypercalcemia. - Digoxin: elevated calcium may enhance digoxin toxicity.

Moderate Interactions (Monitor Closely): - Anticonvulsants (phenytoin, phenobarbital): accelerate vitamin D metabolism, reducing efficacy. - Glucocorticoids: diminish calcium absorption and increase urinary calcium loss. - Bisphosphonates: concurrent use may affect calcium balance; monitor serum levels.